Characteristics | Pre-existing symptoms group | Non pre-existing symptoms group | P value |
---|---|---|---|
Patients | 27 (58.7) | 19 (41.3) | |
Median age at GKRS (year) | 48 (13–83) | 55 (11–76) | 0.040a |
Sex | 0.767b | ||
Male | 10 (37.0) | 8 (42.1) | |
Female | 17 (63.0) | 11 (57.9) | |
Laterality | 0.767b | ||
Left | 17 (63.0) | 11 (57.9) | |
Right | 10 (37.0) | 8 (42.1) | |
Tumour component | 0.440b | ||
Solid | 21 (77.8) | 17 (89.5) | |
Cystic | 6 (22.2) | 2 (10.5) | |
Brainstem contact | 17 (63.0) | 12 (63.2) | 1.000b |
Prior microsurgery | 13 (48.1) | 2 (10.6) | 0.010b |
Tumor typec | |||
A: Primary intracranial | 5 (18.6) | 11 (57.9) | 0.006a |
B: Jugular foramen with intracranial extension | 2 (7.4) | 1 (5.3) | 1.000a |
C: Primary extracranial with foraminal extension | 6 (22.1) | 3 (15.8) | 0.774a |
D: Intra-/extracranial extension (dumb-bell shaped) | 14 (51.9) | 4 (21.1) | 0.034a |
Median tumour volume (cm3) | 4.2 (0.5–13.7) | 1.7 (0.2–10.8) | 0.010a |
Median follow-up period, month | 48 (9–135) | 61 (24–136) | 0.359a |
Median marginal dose (Gy) | 13.0 (12.0–14.0) | 13.0 (12.0–14.0) | 0.861a |
Median maximal dose (Gy) | 26.0 (24.0–28.7) | 26.1 (24.2–28.5) | 0.910a |